Please login to the form below

Not currently logged in
Email:
Password:

New-look Directory from PMGroup launches

Fresh design and updated content shapes the publication’s evolution

Prostate cancer treatment market to treble to £8.2bn by 2023

Astellas Xtandi enzalutamideBut GlobalData predict growth could be hampered by patent loss for Zytiga

Eylea growth closes the gap with Lucentis

Bayer Eylea aflibercept wet AMDBayer/Regeneron’s drug eye disease drug set for blockbuster status

GSK found UK's drug pricing changes a tough sell

GSK - logo on buildingFirm's chief executive met with the government to question the last PPRS update

Kythera bags FDA approval for double chin therapy

FDA headquarters White OakComes as cosmetics industry sees major growth

Harvoni sales rocket in first quarter

gilead-harvoni-ledipasvir-sofosbuvirGilead’s new hepatitis C pill generates stellar revenue

FDA panel backs Amgen's T-Vec for melanoma

Amgen flagApproved by a panel of 22 to one despite questions on its impact on survival

Poor Lantus sales sees Sanofi’s diabetes unit fall

Sanofi receptionFrench firm hit by insulin pricing pressures and soon faces biosimilar threat

Perrigo rejects Mylan again as Teva bites back

MylanThere is much debate over the value of the company’s shares

More money for the NHS – but is this the answer?

Politicians opening their pre-election cheque books can’t put the UK’s health service where it needs to be – but pharma could have a major role to play

Latest appointments

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CAN advertising

Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...

Latest intelligence

MORE MONEY FOR THE NHS – BUT IS THIS THE ANSWER?
Paul Mannu of Cello Health Insight says that politicians opening their pre-election cheque books can’t put the NHS where it needs to be – but pharma can play a major...
Medius Deal Watch
Pharma deals in February 2015
Pfizer and Valeant led the way during a respectable, if not record-breaking, month for mergers, acquisitions and collaborations...
Medius Deal Watch
Medius Deal Watch table for February 2015
The top major pharma mergers, acquisitions and collaborations during the month were led by the Pfizer/Hospira and Salix/Valeant deals...

Infographics